Juliana Bue‐Valleskey

Author

Also Known As

J Bue-Valleskey, J. Bue-Valleskey, J. Bue‐Valleskey, JULIANA M. BUE-VALLESKEY, Juliana Bue-Valleskey, Juliana Bue‐Valleskey, Juliana M Bue-Valleskey, Juliana M. Bue-Valleskey, Juliana M. Bue‐Valleskey, Serrano, Carlos Trescoli

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Praxis für Humangenetik Rainier Clinical Research Center Velocity Clinical Research (United States)ELI-HU Research and Development Non-Profit

About

Juliana Bue‐Valleskey is an author at Eli Lilly (United States) specializing in diabetes, medicine, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.6K
2	Health Sciences	3	3	1.6K
3	Engineering	1	1	110
4	Public Health	1	1	18
5	Biostatistics	1	1	110

Juliana Bue‐Valleskey

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
The role of neuropeptide Y in the antiobesity action of the obese gene product Thomas W. Stephens, Margret B. Basinski, Pamela K. Bristow, Nature ObesityMetabolic SyndromeObese Gene ProductGastrointestinal Peptide HormoneBody Composition	1995	1.5K
Non‐alcoholic fatty liver disease ( <scp>NAFLD</scp> ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes Kenneth Cusi, Arun J. Sanyal, Shuyu Zhang, Diabetes Obesity and Metabolism	2017	180
Mathematical models of diabetes progression Andrea De Gaetano, Thomas A. Hardy, Benoît Beck, American Journal of Physiology-Endocrinology and Metabolism Insulin ResistanceDiabetes ManagementBody CompositionHealth SciencesEngineering	2008	110
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week <scp>PRONTO‐T1D</scp> study Leslie J. Klaff, Dachuang Cao, Mary Anne Dellva, Diabetes Obesity and Metabolism	2020	89
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 John B. Buse, Helena W. Rodbard, Carlos Trescolí Serrano, Diabetes Care	2015	81
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study Tim Heise, Helle Linnebjerg, David E. Coutant, Diabetes Obesity and Metabolism	2020	63
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes Christof Kazda, Juliana Bue‐Valleskey, Jenny Y. Chien, Diabetes Care	2023	54
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial Juliana Bue‐Valleskey, Christof Kazda, Chenchen Ma, Diabetes Care	2023	54
Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: <scp>IMAGINE</scp> 2 randomized trial Melanie J. Davies, David Russell‐Jones, J. L. Selam, Diabetes Obesity and Metabolism	2016	44
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy Maciej T. Małecki, Dachuang Cao, Rong Liu, Diabetes Technology & Therapeutics	2020	36

Page 1